■蛋白质精氨酸甲基转移酶(PRMT)调节与癌症进展有关的几种信号转导途径。最近,据报道,PRMT与抗肿瘤免疫密切相关;然而,其潜在机制尚未在肺腺癌(LUAD)中进行研究.在这项研究中,我们专注于PRMT1和PRMT5,PRMT家族的主要成员。它们在肺癌中的特征与预后相关,免疫谱,并探讨了包括免疫治疗和放疗在内的治疗反应。
■为了了解PRMT1和PRMT5在肿瘤细胞中的功能,我们检查了PRMT1和PRMT5的表达与临床,基因组,和免疫特性,以及对免疫疗法和放射疗法的敏感性。具体来说,我们的研究集中在PRMT1和PRMT5在肿瘤进展中的作用,特别强调干扰素刺激基因(ISGs)和I型干扰素的途径。此外,扩散的影响,迁移,并根据PRMT1和PRMT5在人肺腺癌细胞系中的表达研究侵袭能力。
■通过检查接收器工作特性(ROC)和生存研究,PRMT1和PRMT5被鉴定为诊断和预后的潜在生物标志物。此外,PRMT1或PRMT5的高表达与免疫抑制微环境相关.此外,PRMT1或PRMT5的存在与微卫星不稳定性呈正相关,肿瘤突变负担,和大多数癌症中的新抗原。此外,PRMT1或PRMT5在接受免疫治疗的个体中的预测潜力已得到认可.我们的研究最终揭示了肺腺癌中PRMT1和PRMT5的抑制导致cGAS-STING通路的激活,特别是在辐射之后。在接受放疗且PRMT1或PRMT5表达降低的肺腺癌患者中观察到良好的预后。还发现PRMT1和PRMT5的表达影响增殖,迁移,和人肺腺癌细胞系的侵袭。
■研究结果表明,PRMT1和PRMT5具有作为免疫相关生物标志物用于癌症诊断和预后的潜力。此外,这些生物标志物可作为治疗目标,以增强免疫治疗和放疗在肺腺癌中的疗效.
UNASSIGNED: Protein arginine methyltransferases (PRMTs) regulate several signal transduction pathways involved in cancer progression. Recently, it has been reported that PRMTs are closely related to anti-tumor immunity; however, the underlying mechanisms have yet to be studied in lung adenocarcinoma (LUAD). In this study, we focused on PRMT1 and
PRMT5, key members of the PRMT family. And their signatures in lung carcinoma associated with prognosis, immune profile, and therapeutic response including immunotherapy and radiotherapy were explored.
UNASSIGNED: To understand the function of PRMT1 and
PRMT5 in tumor cells, we examined the association between the expression of PRMT1 and PRMT5 and the clinical, genomic, and immune characteristics, as well as the sensitivity to immunotherapy and radiotherapy. Specifically, our investigation focused on the role of PRMT1 and PRMT5 in tumor progression, with particular emphasis on interferon-stimulated genes (ISGs) and the pathway of type I interferon. Furthermore, the influence of proliferation, migration, and invasion ability was investigated based on the expression of PRMT1 and PRMT5 in human lung adenocarcinoma cell lines.
UNASSIGNED: Through the examination of receiver operating characteristic (ROC) and survival studies, PRMT1 and PRMT5 were identified as potential biomarkers for the diagnosis and prognosis. Additionally, heightened expression of PRMT1 or PRMT5 was associated with immunosuppressive microenvironments. Furthermore, a positive correlation was observed between the presence of PRMT1 or PRMT5 with microsatellite instability, tumor mutational burden, and neoantigens in the majority of cancers. Moreover, the predictive potential of PRMT1 or
PRMT5 in individuals undergoing immunotherapy has been acknowledged. Our study ultimately revealed that the inhibition of PRMT1 and
PRMT5 in lung adenocarcinoma resulted in the activation of the cGAS-STING pathway, especially after radiation. Favorable prognosis was observed in lung adenocarcinoma patients receiving radiotherapy with reduced PRMT1 or PRMT5 expression. It was also found that the expression of PRMT1 and PRMT5 influenced proliferation, migration, and invasion of human lung adenocarcinoma cell lines.
UNASSIGNED: The findings indicate that PRMT1 and
PRMT5 exhibit potential as immune-related biomarkers for the diagnosis and prognosis of cancer. Furthermore, these biomarkers could be therapeutically targeted to augment the efficacy of immunotherapy and radiotherapy in lung adenocarcinoma.